GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » Land And Improvements

Mainz Biomed NV (FRA:4TO) Land And Improvements : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Land And Improvements?

Mainz Biomed NV's land and improvements for the quarter that ended in Dec. 2024 was €0.00 Mil.


Mainz Biomed NV Land And Improvements Historical Data

The historical data trend for Mainz Biomed NV's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Land And Improvements Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Land And Improvements
Get a 7-Day Free Trial - - - - -

Mainz Biomed NV Quarterly Data
Dec19 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mainz Biomed NV Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Mainz Biomed NV Business Description

Traded in Other Exchanges
Address
Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV Headlines

No Headlines